Effect of Oat Beta Glucan in Managing Blood Pressure
Primary Purpose
Elevated Blood Pressure
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
High molecular weight β-glucan oat cookies
Control wheat based cookies
Sponsored by

About this trial
This is an interventional basic science trial for Elevated Blood Pressure
Eligibility Criteria
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial
- Generally healthy male and non-pregnant/lactating female, between the ages of 40-75
- When measured by the ambulatory blood pressure monitor, average systolic blood pressure (between 120 and 150mm Hg) and diastolic blood pressure (between 75 and 100mm Hg)
- Willing to comply with protocol requirements
- Willing to maintain their current weight and activity level throughout the study
- Body mass index 18.5-35kg/m2
Exclusion Criteria:
- Female participant who is pregnant, lactating or planning pregnancy during the course of the trial
- Body mass index ≤ 18.4 and ≥ 35.1 kg/m2
- If there is a history of a secondary cause of hypertension
- Ambulatory blood pressure monitor, systolic blood pressure >150mm Hg or <120mm Hg, diastolic pressure >100mm Hg or <75 mm Hg
- Use of medications containing pseudoephedrine or other vasoconstricting agents
- Antihypertensive drug treatment, regular high dose nonsteroidal anti-inflammatory drugs (NSAID) treatment and the use of cyclosporine or tacrolimus
- Cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attack within six months prior to screening
- Not willing to maintain their regular physical activity level throughout the intervention
- Use of omega-3 fatty acid, herbal supplements or weight loss drugs
- Diagnosis of diabetes type 1 or type 2
- Scheduled elective surgery or other procedures requiring general anaesthesia during the trial
- Any other significant disease or disorder which, in the opinion of the Investigator or study physician, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
- Recent history (within 6 month of screening) or current consumption of >14 drinks per week, (1 drink = 12oz of beer, 5oz of wine or 1.5oz distilled spirits)
- Body weight change over 3.5kg for the past 3 months
- Smokers and tobacco/snuff/nicotine users
- Allergy to oats, wheat, peanut, apple, cherry, blueberry, quinoa, egg white, margarine and vanilla extract.
- Regular consumption of supplements which may influence blood pressure/consumption of food supplements targeted to blood pressure lowering within 30 days before and during the study
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks
Sites / Locations
- Chronic Disease Innovation Centre, Seven Oaks Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Study period 1: β-glucan Oat ; Study period 2: Wheat
Study period 1: Wheat ; Study period 2: β-glucan Oat
Arm Description
For the first period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan. For the second period, the participant will receive food products made from wheat.
For the first period, the participant will receive food products made from wheat. For the second period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan.
Outcomes
Primary Outcome Measures
Mean systolic blood pressure
The mean systolic blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine
Secondary Outcome Measures
Body weight
Body weight will be measured in kg to the nearest 0.1 kg using a digital scale
Waist circumference
Waist circumference in cm will be measured in triplicate, to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape
Mean diastolic blood pressure
The mean diastolic blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine
Mean arterial blood pressure
The mean arterial blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine
Full Information
NCT ID
NCT05029427
First Posted
August 26, 2021
Last Updated
January 24, 2023
Sponsor
University of Manitoba
Collaborators
Agriculture and Agri-Food Canada
1. Study Identification
Unique Protocol Identification Number
NCT05029427
Brief Title
Effect of Oat Beta Glucan in Managing Blood Pressure
Official Title
Effect of Oat Beta Glucan in Managing Blood Pressure: a Randomized Cross-over Pilot Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
November 28, 2021 (Actual)
Primary Completion Date
December 14, 2022 (Actual)
Study Completion Date
December 23, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Manitoba
Collaborators
Agriculture and Agri-Food Canada
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a randomized, double-blinded, cross-over pilot study comparing the effects of ingesting oats containing high molecular weight β-glucan in reducing blood pressure.
Detailed Description
The pilot study will consist of 2 study periods: one treatment period and one control period. The treatment period will provide food products made from oats containing a total of 4 grams per day high molecular weight (HMW) oat β-glucan, whereas, the control period will provide food products made primarily from wheat with no β-glucan. The study will be located at the Chronic Disease Innovation Centre in Seven Oaks General Hospital, Winnipeg, Canada.
The primary objective of this study is to investigate the effect of ingestion of HMW oat β-glucan on ambulatory blood pressure. Participants will be asked to wear an ambulatory blood pressure monitor for 24 hours per day for 3 consecutive days at the beginning and end of each treatment period. This device automatically measures blood pressure every 15-30 minutes during the day and 30 to 60 minutes during the evening.
The study has been designed to be conducted virtually. Participants will consent to receive both treatment and control over two 4-week periods online. The participants will be randomized to different orders of treatment, with a 4 week wash out period in between.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Elevated Blood Pressure
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Treatments will be provided to participants' homes via delivery. The treatments will be in similar looking breakfast cookies that will be prepared and delivered people outside of the clinical trial team.
Allocation
Randomized
Enrollment
23 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Study period 1: β-glucan Oat ; Study period 2: Wheat
Arm Type
Experimental
Arm Description
For the first period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan. For the second period, the participant will receive food products made from wheat.
Arm Title
Study period 1: Wheat ; Study period 2: β-glucan Oat
Arm Type
Experimental
Arm Description
For the first period, the participant will receive food products made from wheat. For the second period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan.
Intervention Type
Other
Intervention Name(s)
High molecular weight β-glucan oat cookies
Intervention Description
Two cookies that contains 4g beta glucan made from oats will be consumed per day.
Intervention Type
Other
Intervention Name(s)
Control wheat based cookies
Intervention Description
Two cookies that made from cream of wheat without beta glucan will be consumed per day.
Primary Outcome Measure Information:
Title
Mean systolic blood pressure
Description
The mean systolic blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine
Time Frame
Day 1 to 3 and day 26-28 of each study period
Secondary Outcome Measure Information:
Title
Body weight
Description
Body weight will be measured in kg to the nearest 0.1 kg using a digital scale
Time Frame
Day 1 and day 28 of each study period
Title
Waist circumference
Description
Waist circumference in cm will be measured in triplicate, to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape
Time Frame
Day 1 and day 28 of each study period
Title
Mean diastolic blood pressure
Description
The mean diastolic blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine
Time Frame
Day 1, 2, and 3 and day 26, 27, and 28 of each study period
Title
Mean arterial blood pressure
Description
The mean arterial blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine
Time Frame
Day 1, 2, and 3 and day 26, 27, and 28 of each study period
Other Pre-specified Outcome Measures:
Title
Dietary fibre by 24 hour recall
Description
Food recalls will be collected through Automated Self-Administered 24-hour dietary assessment tool and analyzed for consumption of dietary fibre
Time Frame
Day 1, 2, and 3 and day 26, 27, and 28 of each study period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participant is willing and able to give informed consent for participation in the trial
Generally healthy male and non-pregnant/lactating female, between the ages of 40-75
When measured by the ambulatory blood pressure monitor, average systolic blood pressure (between 120 and 150mm Hg) and diastolic blood pressure (between 75 and 100mm Hg)
Willing to comply with protocol requirements
Willing to maintain their current weight and activity level throughout the study
Body mass index 18.5-35kg/m2
Exclusion Criteria:
Female participant who is pregnant, lactating or planning pregnancy during the course of the trial
Body mass index ≤ 18.4 and ≥ 35.1 kg/m2
If there is a history of a secondary cause of hypertension
Ambulatory blood pressure monitor, systolic blood pressure >150mm Hg or <120mm Hg, diastolic pressure >100mm Hg or <75 mm Hg
Use of medications containing pseudoephedrine or other vasoconstricting agents
Antihypertensive drug treatment, regular high dose nonsteroidal anti-inflammatory drugs (NSAID) treatment and the use of cyclosporine or tacrolimus
Cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attack within six months prior to screening
Not willing to maintain their regular physical activity level throughout the intervention
Use of omega-3 fatty acid, herbal supplements or weight loss drugs
Diagnosis of diabetes type 1 or type 2
Scheduled elective surgery or other procedures requiring general anaesthesia during the trial
Any other significant disease or disorder which, in the opinion of the Investigator or study physician, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
Recent history (within 6 month of screening) or current consumption of >14 drinks per week, (1 drink = 12oz of beer, 5oz of wine or 1.5oz distilled spirits)
Body weight change over 3.5kg for the past 3 months
Smokers and tobacco/snuff/nicotine users
Allergy to oats, wheat, peanut, apple, cherry, blueberry, quinoa, egg white, margarine and vanilla extract.
Regular consumption of supplements which may influence blood pressure/consumption of food supplements targeted to blood pressure lowering within 30 days before and during the study
Participants who have participated in another research trial involving an investigational product in the past 12 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dylan Mackay, PhD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chronic Disease Innovation Centre, Seven Oaks Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2V 3M3
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD) may be deposited in a repository if required by the journal where the results are published, otherwise it will be available upon request to the principle investigator.
IPD Sharing Time Frame
The data will be available following the publication of the primary results manuscript, and for a period of 25 years.
IPD Sharing Access Criteria
Reasonable request to the principle investigator
Learn more about this trial
Effect of Oat Beta Glucan in Managing Blood Pressure
We'll reach out to this number within 24 hrs